The Biomarkers and Precision Medicine (BPM) and Bioanalytical (BA) Communities are hosting a series of Open Scientific Discussions (OSDs) on Multi-omics in Drug Development. Please join us for the third OSD in the series on July 18th, 12 - 1 pm ET:
Part 3: Multi-omics Integration into Clinical Decision Making
· What does the present regulatory environment look like for the application of multi-omics in clinical decision-making?
· What challenges and considerations does multi-omics testing face, especially for adoption of MS-based proteomics, in clinical studies?
· Case studies where multi-omics approaches have impacted clinical decision makings will be presented.
Discussion Leaders:
Robert Schuck (FDA) & Yuehan Feng (Biognosys)
Organized by: Jurre Kamphorst (Olaris), Iris Qiu (Novartis), Ayuko Ota-Selik (Regeneron) and Jianing Zeng (BMS)
We start at 12:00 ET sharp. To avoid interruptions, please dial in before noon and mute yourself until Q&A starts.
(Please remain on mute unless asking questions)
When: Tuesday, July 18, 2024, 12 pm – 1 pm ET
Where: Please join from your computer, tablet or smartphone.
https://global.gotomeeting.com/join/305789893